UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

mAbs, 2016-01, Vol.8 (1), p.141-149

2016

Link zum Volltext

Verfügbarkeit prüfen

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

Cancer research (Chicago, Ill.), 2007-04, Vol.67 (8), p.3927-3935

2007

Link zum Volltext

Verfügbarkeit prüfen

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (7), p.2882-2889

2005

Link zum Volltext

Verfügbarkeit prüfen

Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3

Cancer Immunology, Immunotherapy, 2006-07, Vol.55 (7), p.785-796

2006

Link zum Volltext

Verfügbarkeit prüfen

Successful Vaccine-Induced Seroconversion by Single-Dose Immunization in the Presence of Measles Virus-Specific Maternal Antibodies

Journal of Virology, 2000-05, Vol.74 (10), p.4652-4657

2000

Link zum Volltext

Verfügbarkeit prüfen

A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

Blood, 2022-11, Vol.140 (Supplement 1), p.11568-11569

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 525: Novel DARPin multi-specific T-cell engager with an improved therapeutic window to overcome dose limiting toxicities in AML therapies

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.525-525

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1890: A solution to T-cell engager toxicity: An anti-CD3 Prodrug DARPin (CD3-PDD) shows no toxicity, but potent anti-tumor activity in a humanized mouse model

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1890-1890

2021

Link zum Volltext

Verfügbarkeit prüfen

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

Immunobiology (1979), 2009-06, Vol.214 (6), p.441-453

2009

Link zum Volltext

Verfügbarkeit prüfen

BiTEs: bispecific antibody constructs with unique anti-tumor activity

Drug discovery today, 2005-09, Vol.10 (18), p.1237-1244

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB221-LB221

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB219-LB219

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB174-LB174

2022

Link zum Volltext

Verfügbarkeit prüfen

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class

Journal of immunotherapy, 2007-11, Vol.30 (8), p.798-807

2007

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine

Vaccine, 2006-03, Vol.24 (12), p.2065-2070

2006

Link zum Volltext

Verfügbarkeit prüfen

MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Molecular Immunology, 2006-03, Vol.43 (8), p.1129-1143

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2910-2910

2022

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3

Cancer research (Chicago, Ill.), 2008, Vol.68 (1), p.143-151

2008

Link zum Volltext

Verfügbarkeit prüfen

T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct

The Journal of immunology (1950), 2003-04, Vol.170 (8), p.4397-4402

2003

Link zum Volltext

Verfügbarkeit prüfen

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA

Journal of immunotherapy, 2009-05, Vol.32 (4), p.341-352

2009

Link zum Volltext

Verfügbarkeit prüfen

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

Cancer Immunology, Immunotherapy, 2006-05, Vol.55 (5), p.503-514

2006

Link zum Volltext

Verfügbarkeit prüfen

Schätzung von Zahlungsbereitschaftsintervallen mit der Choice-Based Conjoint-Analyse

Schmalenbachs Zeitschrift für betriebswirtschaftliche Forschung, 2009, Vol.61 (8), p.838-856

2009

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release

Journal of immunotherapy, 2009-06, Vol.32 (5), p.452-464

2009

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

Cancer Immunology, Immunotherapy, 2009, Vol.58 (1), p.95-109

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(21)
Humans
(19)
Animals
(18)
Biological And Medical Sciences
(13)
Mice
(13)
Immunology
(12)
Medical Sciences
(11)
Business & Economics
(10)
Cd3 Complex - Immunology
(10)
Oncology
(10)
Pharmacology. Drug Treatments
(10)
Social Sciences
(10)
Antibodies, Bispecific - Immunology
(9)
Antineoplastic Agents
(9)
Epithelial Cell Adhesion Molecule
(9)
Antigens, Neoplasm - Immunology
(8)
Bispecific Antibody
(8)
Cell Adhesion Molecules - Immunology
(8)
Female
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3

Successful Vaccine-Induced Seroconversion by Single-Dose Immunization in the Presence of Measles Virus-Specific Maternal Antibodies

A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

Abstract 525: Novel DARPin multi-specific T-cell engager with an improved therapeutic window to overcome dose limiting toxicities in AML therapies

Abstract 1890: A solution to T-cell engager toxicity: An anti-CD3 Prodrug DARPin (CD3-PDD) shows no toxicity, but potent anti-tumor activity in a humanized mouse model

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

BiTEs: bispecific antibody constructs with unique anti-tumor activity

Avidity-Engineered CD3 Engaging DARPin ® Targeting Three Tumor Associated Antigens Induce Strong and Specific T Cell Dependent Killing of AML Cells with Potential for Improved Safety

Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation

Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine

MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3

T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

Schätzung von Zahlungsbereitschaftsintervallen mit der Choice-Based Conjoint-Analyse

Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

Suchergebnisse filtern